Jorge Chaves
Distinguished in Lung Cancer

Dr. Jorge Chaves

Oncology
CommonSpirit Health
Northwest Medical Specialties - Tacoma
1624 South I Street, Suite 105, 
Tacoma, WA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth

Distinguished in Lung Cancer
CommonSpirit Health
Northwest Medical Specialties - Tacoma
1624 South I Street, Suite 105, 
Tacoma, WA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jorge Chaves is an Oncologist in Tacoma, Washington. Dr. Chaves is rated as a Distinguished provider by MediFind in the treatment of Lung Cancer. His top areas of expertise are Familial Colorectal Cancer, Colorectal Cancer, Dehydration, and Lynch Syndrome. Dr. Chaves is currently accepting new patients.

His clinical research consists of co-authoring 2 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 4 clinical trials in the study of Lung Cancer.

Graduate Institution
University Of Texas Medical School At Houston
Residency
Boston University Medical Center, Boston, MA
Specialties
Oncology
Licenses
Internal Medicine in WA
Board Certifications
Internal Medicine
Medical Oncology
Fellowships
Yale University School of Medicine, New Haven, CT
Hospital Affiliations
St Joseph Medical Center
St Anthony Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Coordinated Care
  • HMO
  • MANAGED MEDICAID PLAN
Group Health Cooperative
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Lifewise

Accepted plan types not found. Please verify directly with the provider.

Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
PacificSource
  • PPO
Premera
  • EPO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 17 Less Insurance Carriers -

Locations

Northwest Medical Specialties - Tacoma
1624 South I Street, Suite 105, Tacoma, WA 98405
Call: 253-428-8700

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


14 Clinical Trials

A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
Enrollment Status: Recruiting
Publish Date: November 01, 2023
Intervention Type: Drug
Study Drugs: Ruxolitinib Oral Tablet [Jakafi], Lenalidomide, Methylprednisolone
Study Phase: Phase 1
A Phase 1b/2, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing Cancer
A Phase 1b/2, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing Cancer
Enrollment Status: Completed
Publish Date: October 16, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients With Relapsed or Refractory Lymphoma
A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients With Relapsed or Refractory Lymphoma
Enrollment Status: Terminated
Publish Date: September 17, 2025
Intervention Type: Drug
Study Drug: HMPL-523
Study Phase: Phase 1
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Lung Cancer
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Lung Cancer
Enrollment Status: Completed
Publish Date: December 09, 2024
Intervention Type: Drug
Study Drugs: Etrumadenant, Zimberelimab, Carboplatin, Pemetrexed, Pembrolizumab
Study Phase: Phase 1
Phase I Trial of ZW25 in Patients With Locally Advanced (Unresectable) and/or Metastatic HER2-expressing Cancers
Phase I Trial of ZW25 in Patients With Locally Advanced (Unresectable) and/or Metastatic HER2-expressing Cancers
Enrollment Status: Completed
Publish Date: November 27, 2024
Intervention Type: Drug
Study Drugs: ZW25, Paclitaxel, Capecitabine, Vinorelbine
Study Phase: Phase 1
A Phase I/II Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib in Patients With Metastatic Castration-resistant Prostate Cancer Following Standard of Care Treatment
A Phase I/II Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib in Patients With Metastatic Castration-resistant Prostate Cancer Following Standard of Care Treatment
Enrollment Status: Completed
Publish Date: October 10, 2024
Intervention Type: Drug
Study Drugs: LAE001, Prednisone, Afuresertib
Study Phase: Phase 1/Phase 2
A Phase I, Open-Label Study of GSK1795091 Administered in Combination With Immunotherapies in Participants With Advanced Solid Tumors
A Phase I, Open-Label Study of GSK1795091 Administered in Combination With Immunotherapies in Participants With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: September 23, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1/2 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AO-176
A Phase 1/2 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AO-176
Enrollment Status: Completed
Publish Date: August 22, 2023
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination With Nivolumab in Patients With Advanced/Metastatic Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer
A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination With Nivolumab in Patients With Advanced/Metastatic Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: March 17, 2023
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1b/2 Study of ARRY-382 in Combination With Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients With Advanced Solid Tumors
A Phase 1b/2 Study of ARRY-382 in Combination With Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: June 16, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase III Open-label, Multicenter Trial of Maintenance Therapy With Avelumab (MSB0010718C) Versus Continuation of First-line Chemotherapy in Subjects With Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro-esophageal Junction
A Phase III Open-label, Multicenter Trial of Maintenance Therapy With Avelumab (MSB0010718C) Versus Continuation of First-line Chemotherapy in Subjects With Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro-esophageal Junction
Enrollment Status: Completed
Publish Date: June 09, 2022
Intervention Type: Drug, Other
Study Phase: Phase 3
A Phase Ib Trial of LEE011 in Combination With Everolimus (RAD001) and Exemestane in the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
A Phase Ib Trial of LEE011 in Combination With Everolimus (RAD001) and Exemestane in the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: April 13, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: June 02, 2020
Intervention Type: Drug
Study Phase: Phase 1
An Open Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) in Combination With RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) Compared With RCHOP Alone as Frontline Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Grade 3b
An Open Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) in Combination With RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) Compared With RCHOP Alone as Frontline Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Grade 3b
Enrollment Status: Terminated
Publish Date: March 11, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 13 Less Clinical Trials

2 Total Publications

A phase 1 study of ABT-806 in subjects with advanced solid tumors.
A phase 1 study of ABT-806 in subjects with advanced solid tumors.
Journal: Investigational new drugs
Published: February 18, 2015
View All 2 Publications
Similar Doctors
Elite in Lung Cancer
Dr. Christina S. Baik
Oncology | Hematology Oncology
Elite in Lung Cancer
Dr. Christina S. Baik
Oncology | Hematology Oncology

The Association Of University Physicians

825 Eastlake Ave E, 
Seattle, WA 
 (26.8 miles away)
206-288-1000
Languages Spoken:
English, Castilian, Hindi, Korean, Punjabi, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Christina Baik is an Oncologist and a Hematologist Oncology provider in Seattle, Washington. Dr. Baik is rated as an Elite provider by MediFind in the treatment of Lung Cancer. Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, and Small Cell Lung Cancer (SCLC). Dr. Baik is currently accepting new patients.

Sid Devarakonda
Elite in Lung Cancer
Dr. Sid Devarakonda
Oncology
Elite in Lung Cancer
Dr. Sid Devarakonda
Oncology

Medical Oncology - Swedish Cancer Institute First Hill

1221 Madison Street, 0, 
Seattle, WA 
 (25.8 miles away)
206-386-3751
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. Devarakonda trained and worked on faculty at the Washington University in St. Louis before joining Swedish. His research is focused on understanding cancers utilizing sequencing technologies. He has an excellent understanding of the latest advances in thoracic oncology (lung cancer, thymic malignancies, mesothelioma). He believes in providing the same level of care for his patients that he expects for his own family. His list of peer-reviewed scientific publications can be accessed here https://pubmed.ncbi.nlm.nih.gov/?term=Devarakonda+S&cauthor_id=34591593. Dr. Devarakonda is rated as a Distinguished provider by MediFind in the treatment of Lung Cancer. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Lung Adenocarcinoma.

Rafael Santana
Elite in Lung Cancer
Dr. Rafael Santana
Oncology
Elite in Lung Cancer
Dr. Rafael Santana
Oncology

Medical Oncology - Swedish Cancer Institute First Hill

1221 Madison Street, 0, 
Seattle, WA 
 (25.8 miles away)
206-386-3751
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Cancer is a terrible disease—often one of the most frightening and uncertain experiences a person can face. My philosophy is to approach every patient with a blend of deep empathy and evidence-based treatment options, empowering them to make informed decisions that align with their values, needs, and goals. I believe that compassionate care and scientific rigor form the foundation of meaningful, personalized cancer care. Dr. Santana is rated as a Distinguished provider by MediFind in the treatment of Lung Cancer. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Pleuropulmonary Blastoma.

VIEW MORE LUNG CANCER DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chaves's expertise for a condition
ConditionClose
    • Distinguished
    • Chronic Lymphocytic Leukemia (CLL)
      Dr. Chaves is
      Distinguished
      . Learn about Chronic Lymphocytic Leukemia (CLL).
      See more Chronic Lymphocytic Leukemia (CLL) experts
    • Colorectal Cancer
      Dr. Chaves is
      Distinguished
      . Learn about Colorectal Cancer.
      See more Colorectal Cancer experts
    • Dehydration
      Dr. Chaves is
      Distinguished
      . Learn about Dehydration.
      See more Dehydration experts
    • Diffuse Large B-Cell Lymphoma (DLBCL)
      Dr. Chaves is
      Distinguished
      . Learn about Diffuse Large B-Cell Lymphoma (DLBCL).
      See more Diffuse Large B-Cell Lymphoma (DLBCL) experts
    • Familial Colorectal Cancer
      Dr. Chaves is
      Distinguished
      . Learn about Familial Colorectal Cancer.
      See more Familial Colorectal Cancer experts
    • Familial Pancreatic Cancer
      Dr. Chaves is
      Distinguished
      . Learn about Familial Pancreatic Cancer.
      See more Familial Pancreatic Cancer experts
    View All 19 Distinguished Conditions
    • Advanced
    • Adult Immune Thrombocytopenia
      Dr. Chaves is
      Advanced
      . Learn about Adult Immune Thrombocytopenia.
      See more Adult Immune Thrombocytopenia experts
    • Adult Soft Tissue Sarcoma
      Dr. Chaves is
      Advanced
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    • Agranulocytosis
      Dr. Chaves is
      Advanced
      . Learn about Agranulocytosis.
      See more Agranulocytosis experts
    • Ampullary Cancer
      Dr. Chaves is
      Advanced
      . Learn about Ampullary Cancer.
      See more Ampullary Cancer experts
    • Anal Cancer
      Dr. Chaves is
      Advanced
      . Learn about Anal Cancer.
      See more Anal Cancer experts
    • Anemia
      Dr. Chaves is
      Advanced
      . Learn about Anemia.
      See more Anemia experts
    View All 54 Advanced Conditions
    • Experienced
    • Acinic Cell Carcinoma of Salivary Glands
      Dr. Chaves is
      Experienced
      . Learn about Acinic Cell Carcinoma of Salivary Glands.
      See more Acinic Cell Carcinoma of Salivary Glands experts
    • Acute Lymphoblastic Leukemia (ALL)
      Dr. Chaves is
      Experienced
      . Learn about Acute Lymphoblastic Leukemia (ALL).
      See more Acute Lymphoblastic Leukemia (ALL) experts
    • Acute Mountain Sickness
      Dr. Chaves is
      Experienced
      . Learn about Acute Mountain Sickness.
      See more Acute Mountain Sickness experts
    • Acute Myeloblastic Leukemia with Maturation
      Dr. Chaves is
      Experienced
      . Learn about Acute Myeloblastic Leukemia with Maturation.
      See more Acute Myeloblastic Leukemia with Maturation experts
    • Acute Myeloblastic Leukemia without Maturation
      Dr. Chaves is
      Experienced
      . Learn about Acute Myeloblastic Leukemia without Maturation.
      See more Acute Myeloblastic Leukemia without Maturation experts
    • Acute Myeloid Leukemia (AML)
      Dr. Chaves is
      Experienced
      . Learn about Acute Myeloid Leukemia (AML).
      See more Acute Myeloid Leukemia (AML) experts
    View All 162 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.